A Phase 1/2 interventional study of axitinib and axitinib in Carcinoma, Non-Small Cell Lung, sponsored by Pfizer. Completed at 52 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-28.
Sponsored by Pfizer · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer — 15 open to participants now, 26 under way, 5 of them phase 3. Carcinoma, Non-Small-Cell Lung · Pfizer.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, this one is the 38th largest by enrollment of the 136 interventional ones that give a count, is one of 2 that started in 2009, is one of 13 in phase 1/2, and was the 37th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →15 of the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Australia, China and 8 more countries
Ages 18+
Pfizer · Sites in United States, China, France and 6 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
Pfizer · Sites in United States, Argentina, Australia and 26 more countries
Ages 18+
By country, each count listing its studies:
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
158 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 69 · Phase 2 58 · Phase 3 18 · Phase 4 4
First in 1999; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 79 across the 136 interventional studies, 97 across the 17 observational. Of the 123 that completed or were terminated, 70 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
4 of the studies in Carcinoma, Non-Small-Cell Lung by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07567352PfizerA Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment | 2027-03-01 |
| NCT04389632Seagen, a wholly owned subsidiary of PfizerA Study of Sigvotatug Vedotin in Advanced Solid Tumors | 2027-06-16 |
| NCT05538130PfizerA Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | 2027-08-31 |
| NCT05355701PfizerA Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | 2027-08-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 158 studies in Carcinoma, Non-Small-Cell Lung by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Axitinib (continuous) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
Drug: axitinib
Axitinib (modified) + Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
Drug: axitinib
pemetrexed and cisplatin
Drug: chemotherapy
Axitinib interrupted before each chemo cycle (Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles followed by axitinib maintenance
Drug: axitinib
pemetrexed and cisplatin
Drug: chemotherapy
5mg BID po up to max 10mg BID po
Also known as: AG-013736
5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy
Also known as: AG-013736
Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
Also known as: alimta
5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy
Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
Also known as: alimta
Progression-Free Survival (PFS)
Time in months from the date of randomization to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus minus the date of randomization plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]); death was determined from AE data (where the outcome was "Death") or from the end of study data.
Time frame: Phase 2 baseline until the date of first documented progression or death due to any cause or initiation of subsequent anticancer therapy, assessed every 6 weeks up to 84 weeks
Overall Survival (OS)
Time in months from the date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death).
Time frame: Baseline until death or collected bimonthly following discontinuation of study treatment until at least 1 year after randomization of the last participant
Percentage of Participants With Objective Response (OR)
Percentage of participants with OR based assessment of confirmed complete response (CR)/confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors(RECIST).Confirmed responses: those persist on repeat imaging study at least 4 weeks after initial documentation of response.CR: disappearance of all lesions (target/non target) and no appearance of new lesions.PR: those with at least 30 % decrease in sum of longest dimensions of target lesions taking as reference baseline sum longest dimensions,without progression of non target lesions and no appearance of new lesions.
Time frame: Phase 2 baseline until the date of first documented progression or discontinuation from the study due to any cause or initiation of subsequent anticancer therapy, assessed every 6 weeks up to 84 weeks
Duration of Response (DR)
Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause, whichever occurs first. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
Time frame: Phase 2 baseline until the date of first documented progression or discontinuation from the study due to any cause or initiation of subsequent anticancer therapy, assessed every 6 weeks up to 84 weeks
Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Symptom Severity Score
Symptom severity score is comprised of average of 13 MDASI core items (pain, fatigue, nausea, disturbed sleep, distressed, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sadness, vomiting, numbness or tingling) and ranges from 0 to 10. Participants were asked to rate severity of each symptom at their worst in last 24 hours; each item rated from 0 to 10, with 0 = symptom not present and 10 = as bad as you can imagine. Lower scores indicated better outcome.
Time frame: Phase 2 baseline (Cycle1/Day1), Cycle1/Day8, then Day 1 and 8 of each cycle of chemotherapy (C) up to CycleC6, Day 1 of each cycle of single-agent phase (A) up to CycleA8 and end of treatment (EOT)
Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Symptom Interference Score
Symptom interference score is comprised of average of 6 function items from MDASI core (general activity, mood, work, relations with others, walking, and enjoyment of life) and ranges from 0 to 10. Participants were asked to rate how much symptoms have interfered in last 24 hours; each item rated from 0 to 10, with 0 = did not interfere and 10 = interfered completely. Lower scores indicated better outcome.
Time frame: Phase 2 baseline (Cycle1/Day1), Cycle1/Day8, then Day 1 and 8 of each cycle of chemotherapy (C) up to CycleC6, Day 1 of each cycle of single-agent phase (A) up to CycleA8 and EOT
| Milestone | Axitinib + Pemetrexed/Cisplatin (Phase 1) | Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2) | Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2) | Pemetrexed/Cisplatin (Phase 2) |
|---|---|---|---|---|
| Started | 10 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 10 | 0 | 0 | 0 |
| Withdrew: Death | 6 | 0 | 0 | 0 |
| Withdrew: Other | 4 | 0 | 0 | 0 |
| Milestone | Axitinib + Pemetrexed/Cisplatin (Phase 1) | Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2) | Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2) | Pemetrexed/Cisplatin (Phase 2) |
|---|---|---|---|---|
| Started | 0 | 55 | 58 | 57 |
| Treated | 0 | 55 | 58 | 55 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 55 | 58 | 57 |
| Withdrew: Death | 0 | 37 | 48 | 31 |
| Withdrew: Protocol violation | 0 | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 4 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 |
| Withdrew: Other | 0 | 1 | 2 | 4 |
| Withdrew: Study terminated by sponsor | 0 | 13 | 7 | 14 |
| Withdrew: Randomized but not treated | 0 | 0 | 0 | 2 |
Time in months from the date of randomization to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus minus the date of randomization plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]); death was determined from AE data (where the outcome was "Death") or from the end of study data.
| months | Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2) | Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2) | Pemetrexed/Cisplatin (Phase 2) |
|---|---|---|---|
| Progression-Free Survival (PFS) | 8.0 (6.7 to 10.0) | 8.1 (6.8 to 9.9) | 7.1 (5.8 to 9.4) |
Time in months from the date of randomization to date of death due to any cause. OS was calculated as (the death date minus the date of randomization plus 1) divided by 30.4. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death).
| months | Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2) | Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2) | Pemetrexed/Cisplatin (Phase 2) |
|---|---|---|---|
| Overall Survival (OS) | 17.0 (12.6 to 22.5) | 14.7 (11.5 to 18.1) | 15.9 (11.1 to NA) |
Percentage of participants with OR based assessment of confirmed complete response (CR)/confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors(RECIST).Confirmed responses: those persist on repeat imaging study at least 4 weeks after initial documentation of response.CR: disappearance of all lesions (target/non target) and no appearance of new lesions.PR: those with at least 30 % decrease in sum of longest dimensions of target lesions taking as reference baseline sum longest dimensions,without progression of non target lesions and no appearance of new lesions.
| percentage of participants | Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2) | Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2) | Pemetrexed/Cisplatin (Phase 2) |
|---|---|---|---|
| Percentage of Participants With Objective Response (OR) | 45.5 (32.0 to 59.4) | 39.7 (27.0 to 53.4) | 26.3 (15.5 to 39.7) |
Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause, whichever occurs first. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response.
| months | Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2) | Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2) | Pemetrexed/Cisplatin (Phase 2) |
|---|---|---|---|
| Duration of Response (DR) | 7.82 (5.6 to 11.4) | 6.73 (5.0 to 7.8) | 7.10 (4.2 to 24.7) |
Symptom severity score is comprised of average of 13 MDASI core items (pain, fatigue, nausea, disturbed sleep, distressed, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sadness, vomiting, numbness or tingling) and ranges from 0 to 10. Participants were asked to rate severity of each symptom at their worst in last 24 hours; each item rated from 0 to 10, with 0 = symptom not present and 10 = as bad as you can imagine. Lower scores indicated better outcome.
| units on a scale | Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2) | Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2) | Pemetrexed/Cisplatin (Phase 2) |
|---|---|---|---|
| Phase 2 baseline (CycleC1/Day 1), (n= 55, 55, 53) | 1.75 (1.32 to 2.18) | 2.09 (1.67 to 2.50) | 1.80 (1.33 to 2.27) |
| Change at CycleC1/Day 8, (n= 49, 49, 50) | 1.55 (1.09 to 2.02) | 0.36 (0.00 to 0.72) | 0.95 (0.56 to 1.34) |
| Change at CycleC2/Day1 (n= 51, 51, 41) | 0.12 (-0.26 to 0.49) | -0.05 (-0.46 to 0.35) | 0.39 (0.01 to 0.77) |
| Change at CycleC2/Day8 (n= 39, 38, 34) | 1.52 (0.98 to 2.06) | 0.39 (-0.14 to 0.92) | 0.69 (0.24 to 1.13) |
| Change at CycleC3/Day1 (n= 45, 47, 39) | 0.57 (0.16 to 0.97) | 0.29 (-0.13 to 0.71) | 0.32 (-0.15 to 0.79) |
| Change at CycleC3/Day8 (n= 38, 35, 32) | 1.33 (0.75 to 1.92) | 0.87 (0.18 to 1.56) | 1.15 (0.61 to 1.68) |
| Change at CycleC4/Day1 (n= 43, 43, 38) | 0.85 (0.28 to 1.42) | 0.48 (-0.06 to 1.02) | 0.37 (-0.05 to 0.79) |
| Change at CycleC4/Day8 (n= 33, 33, 27) | 1.37 (0.64 to 2.09) | 0.90 (0.30 to 1.51) | 1.48 (0.77 to 2.19) |
| Change at CycleC5/Day1 (n= 35, 34, 29) | 0.59 (0.05 to 1.12) | 0.48 (-0.17 to 1.12) | 0.72 (0.25 to 1.18) |
| Change at CycleC5/Day8 (n= 29, 26, 25) | 1.19 (0.38 to 2.00) | 0.82 (0.10 to 1.55) | 1.16 (0.46 to 1.87) |
| Change at CycleC6/Day1 (n= 27, 28, 28) | 0.67 (0.04 to 1.30) | 0.42 (-0.22 to 1.06) | 0.67 (0.11 to 1.23) |
| Change at CycleC6/Day8 (n= 25, 25, 21) | 1.44 (0.71 to 2.17) | 0.85 (0.23 to 1.47) | 1.28 (0.48 to 2.08) |
| Change at CycleA1/Day1 (n= 35, 33, 21) | 0.63 (0.27 to 0.99) | 0.24 (-0.32 to 0.79) | 0.68 (-0.09 to 1.45) |
| Change at CycleA2/Day1 (n= 32, 30, 14) | 0.36 (-0.11 to 0.83) | -0.01 (-0.55 to 0.54) | 0.14 (-0.49 to 0.77) |
| Change at CycleA3/Day1 (n= 27, 26, 10) | 0.25 (-0.30 to 0.79) | 0.01 (-0.63 to 0.65) | 0.12 (-0.38 to 0.63) |
| Change at CycleA4/Day1 (n= 22, 25, 0) | 0.03 (-0.65 to 0.70) | 0.07 (-0.56 to 0.70) | NA (NA to NA) |
| Change at CycleA5/Day1 (n= 17, 23, 12) | 0.19 (-0.78 to 1.16) | -0.12 (-0.73 to 0.48) | 0.30 (-0.37 to 0.96) |
| Change at CycleA6/Day1 (n= 17, 16, 10) | 0.10 (-0.56 to 0.77) | -0.23 (-1.21 to 0.76) | 0.14 (-0.83 to 1.11) |
| Change at CycleA7/Day1 (n= 15, 15, 0) | -0.26 (-0.99 to 0.47) | -0.33 (-1.37 to 0.70) | NA (NA to NA) |
| Change at CycleA8/Day1 (n= 15, 14, 10) | -0.28 (-0.91 to 0.35) | 0.30 (-0.76 to 1.36) | 0.02 (-1.15 to 1.20) |
| Change at CycleA9/Day1 (n= 13, 11, 0) | -0.46 (-1.29 to 0.38) | 0.34 (-0.51 to 1.19) | NA (NA to NA) |
| Change at CycleA10/Day1 (n= 0, 10, 0) | NA (NA to NA) | 0.61 (-0.38 to 1.59) | NA (NA to NA) |
| Change at EOT (n= 40, 35, 31) | 0.66 (0.12 to 1.20) | 1.02 (0.40 to 1.63) | 0.99 (0.33 to 1.64) |
Symptom interference score is comprised of average of 6 function items from MDASI core (general activity, mood, work, relations with others, walking, and enjoyment of life) and ranges from 0 to 10. Participants were asked to rate how much symptoms have interfered in last 24 hours; each item rated from 0 to 10, with 0 = did not interfere and 10 = interfered completely. Lower scores indicated better outcome.
| units on a scale | Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2) | Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2) | Pemetrexed/Cisplatin (Phase 2) |
|---|---|---|---|
| Phase 2 baseline (CycleC1/Day 1), (n= 55, 55, 53) | 2.36 (1.64 to 3.08) | 2.97 (2.27 to 3.68) | 2.64 (1.92 to 3.37) |
| Change at CycleC1/Day 8, (n= 49, 49, 50) | 1.48 (0.80 to 2.16) | -0.03 (-0.75 to 0.68) | 0.81 (0.27 to 1.36) |
| Change at CycleC2/Day1 (n= 51, 51, 41) | 0.27 (-0.21 to 0.75) | -0.24 (-0.76 to 0.29) | 0.30 (-0.25 to 0.84) |
| Change at CycleC2/Day8 (n= 39, 38, 34) | 2.00 (1.07 to 2.93) | 0.03 (-0.61 to 0.66) | 0.52 (0.05 to 0.99) |
| Change at CycleC3/Day1 (n= 45, 47, 39) | 0.64 (0.07 to 1.21) | -0.21 (-0.81 to 0.40) | 0.03 (-0.41 to 0.46) |
| Change at CycleC3/Day8 (n= 38, 35, 32) | 1.54 (0.57 to 2.50) | 0.28 (-0.46 to 1.03) | 0.41 (-0.00 to 0.82) |
| Change at CycleC4/Day1 (n= 43, 43, 38) | 0.72 (-0.18 to 1.62) | 0.11 (-0.50 to 0.73) | 0.28 (-0.16 to 0.71) |
| Change at CycleC4/Day8 (n= 33, 33, 27) | 1.39 (0.20 to 2.58) | 1.08 (0.23 to 1.92) | 1.20 (0.48 to 1.93) |
| Change at CycleC5/Day1 (n= 35, 34, 29) | 0.14 (-0.67 to 0.95) | -0.05 (-0.88 to 0.78) | 0.49 (-0.10 to 1.09) |
| Change at CycleC5/Day8 (n= 29, 26, 25) | 0.78 (-0.42 to 1.97) | 0.88 (-0.19 to 1.94) | 0.76 (-0.03 to 1.55) |
| Change at CycleC6/Day1 (n= 27, 28, 28) | 0.18 (-0.76 to 1.12) | 0.17 (-0.68 to 1.01) | 0.66 (-0.04 to 1.36) |
| Change at CycleC6/Day8 (n= 25, 25, 21) | 1.00 (-0.16 to 2.16) | 1.04 (0.17 to 1.91) | 1.20 (0.32 to 2.08) |
| Change at CycleA1/Day1 (n= 35, 33, 21) | 0.49 (-0.20 to 1.18) | 0.39 (-0.34 to 1.13) | 0.96 (0.28 to 1.64) |
| Change at CycleA2/Day1 (n= 32, 30, 14) | 0.25 (-0.52 to 1.02) | 0.16 (-0.67 to 0.98) | 0.10 (-0.82 to 1.01) |
| Change at CycleA3/Day1 (n= 27, 26, 10) | 0.02 (-0.82 to 0.87) | -0.20 (-1.15 to 0.76) | 0.27 (-0.43 to 0.96) |
| Change at CycleA4/Day1 (n= 22, 25, 0) | 0.33 (-0.43 to 1.10) | 0.23 (-0.58 to 1.05) | NA (NA to NA) |
| Change at CycleA5/Day1 (n= 17, 23, 12) | 0.36 (-0.54 to 1.27) | 0.12 (-1.02 to 1.27) | 0.40 (-0.56 to 1.37) |
| Change at CycleA6/Day1 (n= 17, 16, 10) | 0.16 (-0.47 to 0.79) | 0.28 (-0.82 to 1.39) | 0.12 (-0.92 to 1.15) |
| Change at CycleA7/Day1 (n= 15, 15, 0) | 0.12 (-0.68 to 0.92) | 0.00 (-1.14 to 1.15) | NA (NA to NA) |
| Change at CycleA8/Day1 (n= 15, 14, 10) | -0.07 (-0.96 to 0.82) | 0.30 (-0.70 to 1.29) | 0.42 (-0.39 to 1.23) |
| Change at CycleA9/Day1 (n= 13, 11, 0) | -0.13 (-1.03 to 0.77) | 1.05 (0.09 to 2.00) | NA (NA to NA) |
| Change at CycleA10/Day1 (n= 0, 10, 0) | NA (NA to NA) | 1.03 (0.06 to 2.01) | NA (NA to NA) |
| Change at EOT (n= 40, 35, 31) | 0.69 (-0.26 to 1.64) | 0.69 (-0.22 to 1.59) | 0.91 (0.06 to 1.77) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Axitinib + Pemetrexed/Cisplatin (Phase 1) | — | 1/10 (10%) | 10/10 (100%) |
| Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2) | — | 19/55 (34.5%) | 54/55 (98.2%) |
| Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2) | — | 20/58 (34.5%) | 56/58 (96.6%) |
| Pemetrexed/Cisplatin (Phase 2) | — | 13/55 (23.6%) | 54/55 (98.2%) |
| Event | Axitinib + Pemetrexed/Cisplatin (Phase 1) | Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2) | Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2) | Pemetrexed/Cisplatin (Phase 2) |
|---|---|---|---|---|
| Respiratory tract infectionInfections and infestations | 1/10 | 0/55 | 0/58 | 0/55 |
| VomitingGastrointestinal disorders | 0/10 | 5/55 | 2/58 | 2/55 |
| NauseaGastrointestinal disorders | 0/10 | 4/55 | 1/58 | 1/55 |
| DehydrationMetabolism and nutrition disorders | 0/10 | 3/55 | 3/58 | 0/55 |
| Chest painGeneral disorders | 0/10 | 0/55 | 1/58 | 2/55 |
| PneumoniaInfections and infestations | 0/10 | 2/55 | 0/58 | 0/55 |
| PresyncopeNervous system disorders | 0/10 | 2/55 | 0/58 | 0/55 |
| HypertensionVascular disorders | 0/10 | 2/55 | 0/58 | 0/55 |
| AnaemiaBlood and lymphatic system disorders | 0/10 | 0/55 | 2/58 | 1/55 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/10 | 0/55 | 2/58 | 0/55 |
| Event | Axitinib + Pemetrexed/Cisplatin (Phase 1) | Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2) | Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2) | Pemetrexed/Cisplatin (Phase 2) |
|---|---|---|---|---|
| FatigueGeneral disorders | 8/10 | 27/55 | 25/58 | 25/55 |
| Decreased appetiteMetabolism and nutrition disorders | 7/10 | 29/55 | 28/58 | 23/55 |
| HypertensionVascular disorders | 7/10 | 37/55 | 28/58 | 6/55 |
| NauseaGastrointestinal disorders | 6/10 | 37/55 | 30/58 | 32/55 |
| AnaemiaBlood and lymphatic system disorders | 5/10 | 7/55 | 19/58 | 23/55 |
| NeutropeniaBlood and lymphatic system disorders | 5/10 | 17/55 | 12/58 | 15/55 |
| DiarrhoeaGastrointestinal disorders | 5/10 | 22/55 | 20/58 | 9/55 |
| AstheniaGeneral disorders | 5/10 | 9/55 | 11/58 | 7/55 |
| VomitingGastrointestinal disorders | 4/10 | 26/55 | 19/58 | 14/55 |
| ConstipationGastrointestinal disorders | 4/10 | 20/55 | 15/58 | 23/55 |
| Age, Customized(participants) | Axitinib + Pemetrexed/Cisplatin (Phase 1) | Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2) | Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2) | Pemetrexed/Cisplatin (Phase 2) | Total |
|---|---|---|---|---|---|
| Less Than 65 Years | 5 | 35 | 34 | 43 | 117 |
| Greater Than or Equal to 65 Years | 5 | 20 | 24 | 14 | 63 |
| Sex: Female, Male(Participants) | Axitinib + Pemetrexed/Cisplatin (Phase 1) | Axitinib (Continuous) + Pemetrexed/Cisplatin (Phase 2) | Axitinib (Modified) + Pemetrexed/Cisplatin (Phase 2) | Pemetrexed/Cisplatin (Phase 2) | Total |
|---|---|---|---|---|---|
| Female | 1 | 21 | 21 | 20 | 63 |
| Male | 9 | 34 | 37 | 37 | 117 |
The record gives a start of Jan 2009, a primary completion of Mar 2011 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Axitinib
Carcinoma, Non-Small-Cell Lung →